Login / Signup

Mitoxantrone in NMO Spectrum Disorder in a Large Multicenter Cohort in French Caribbean.

Hugo ChaumontNicolas BérardJean-Pierre KaramQuentin LobjoisBenoit TressieresAissatou SignateAnnie LannuzelPhilippe Cabre
Published in: Neurology(R) neuroimmunology & neuroinflammation (2023)
MiTX is an effective and safe treatment for most of our patients, drastically less expensive than new molecules, and could be allowed in NMOSD Afro-descendant patients in geographical areas where access to care is difficult.
Keyphrases
  • end stage renal disease
  • ejection fraction
  • newly diagnosed
  • chronic kidney disease
  • peritoneal dialysis
  • prognostic factors
  • clinical trial
  • quality improvement
  • chronic pain
  • combination therapy